Evidence map›Paper›PMID 42726875›Full record

ArticleScience advances2026

Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1.

Xin Zhang, Qian Hao, Wenyue Yang, Yunbo Yu, Qingya Yan, Zhenhua Wu, Zhihuang Hu, Xiang Zhou, Jialei Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xin ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0009-0005-6887-8316
Qian HaoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0009-0005-2969-4194
Wenyue YangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0009-0003-9168-1824
Yunbo YuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0009-0004-2219-1597
Qingya YanDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0009-0006-7779-017X
Zhenhua WuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Zhihuang HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0002-6547-3832
Xiang ZhouDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0000-0002-1172-7948
Jialei WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0001-9977-2219

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of immune checkpoint blockade (ICB) in lung adenocarcinoma (LUAD) is limited by primary or acquired resistance, especially in genetically defined subsets. We investigated the impact of

Indexed as

Adenocarcinoma of LungImmunotherapyLung NeoplasmsMutationOsteopontinProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53AnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceKRAS protein, humanOsteopontinProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53

Identifiers

PMID42726875
PMCPMC13564959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.